Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 9/20 | 0.59 |
| ▸ | ITGAV | P06756 | 7/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.49 |
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240965 | 1.00 | ITGB3 (0.59) | ITGB3ITGAVTSHRSMN1; SMN2L3MBTL1 | |
| SCHEMBL7370194 | 0.97 | TSHR (0.58) | ITGB3ITGAVTSHRSMN1; SMN2L3MBTL1 | |
| SCHEMBL6777422 | 0.96 | ITGB3 (0.54) | ITGB3ITGAVTSHRSMN1; SMN2L3MBTL1 | |
| SCHEMBL6778483 | 0.92 | SUCNR1 (0.53) | ITGB3ITGAVSUCNR1ITGA2B | |
| SCHEMBL7341225 | 0.92 | SUCNR1 (0.53) | ITGB3ITGAVTSHRSMN1; SMN2L3MBTL1 | |
| SCHEMBL6774333 | 0.92 | ITGB3 (0.50) | ITGB3ITGAVTSHRSMN1; SMN2SUCNR1 | |
| SCHEMBL6777032 | 0.92 | ITGB3 (0.50) | ITGB3ITGAVTSHRSMN1; SMN2SUCNR1 | |
| SCHEMBL6778398 | 0.91 | ITGB3 (0.59) | ITGB3ITGAVL3MBTL1LMNA | |
| SCHEMBL27503084 | 0.91 | ITGB3 (0.50) | ITGB3ITGAVTSHRSUCNR1NAMPT | |
| SCHEMBL6779808 | 0.90 | ITGB3 (0.49) | ITGB3ITGAVTSHRSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | GENESTE HERVE (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | BASF AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| EP-1239877-B1 | COMPOSITION COMPRISING A TNF-ALPHA INHIBITOR AND AN INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONIST | ABBOTT GMBH & CO KG (DE) | 2008-01-09 | — | — | EP | disclosed |
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | GENESTE HERVE | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | ITGB3, IL6ST, IL1RN | ITGB3 1/4885ITGAV 11/4885TSHR 245/4885 |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | EDNRB, EDNRA, ITGB3 | ITGB3 3/4885ITGAV 4/4885TSHR 664/4885 |
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | ITGB3, ITGAV, ITGB1 | ITGB3 1/4885ITGAV 2/4885TSHR 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.